latest update:
[TrialBase DB]

trial summary · NCT07703436

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Trial record from the TrialBase DB dataset, status RECRUITING, condition Grade 2 IDH1-mutant Glioma, sponsored by Nuvation Bio Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07703436phase PHASE2enrollment 40start 2027-03

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Source record: https://clinicaltrials.gov/study/NCT07703436

Facts

registry idNCT07703436
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionGrade 2 IDH1-mutant Glioma
sponsorNuvation Bio Inc.
sponsor classINDUSTRY
enrollment40
start date2027-03
primary completion2030-09
completion2032-03
results postednot reported

Conditions

  • Grade 2 IDH1-mutant Glioma
  • Grade 3 IDH1-mutant Glioma
  • Glioma
  • IDH1-mutant Glioma
  • Oligodendroglioma
  • Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted
  • Astrocytoma IDH Mutant Grade 3
  • Astrocytoma IDH Mutant Grade 2

Interventions

  • Safusidenib

Countries

  • United States

Intervention types: DRUG

Work with this record